Adjuvant therapy for stage II colorectal cancer: Who and with what?

Current Treatment Options in Gastroenterology

Volumn 9, Issue 3, 2006, Pages 272-280

  Chung, Ki Young Y ^a   Kelsen, David ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATROPINE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; SEMUSTINE; VINCRISTINE; WARFARIN;

ABDOMINAL CRAMP; ACNE; BIOLOGICAL THERAPY; BLEEDING; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 18Q; CHROMOSOME LOSS; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLON OBSTRUCTION; COLON PERFORATION; COLORECTAL CANCER; COMORBIDITY; CORONARY ARTERY SPASM; DIAPHORESIS; DIARRHEA; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENTIATION; EYE DISEASE; FEVER; HAND FOOT SYNDROME; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LIFE EXPECTANCY; LYMPH NODE METASTASIS; MALAISE; MEDICAL DECISION MAKING; MICROSATELLITE INSTABILITY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHARYNX DISEASE; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SURVIVAL RATE; SYSTEMIC THERAPY; THROMBOEMBOLISM; WEAKNESS;

EID: 33744958201     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-006-0046-z     Document Type: Review

References (33)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
2. Greene F, Page DL, Fleming ID, et al. The AJCC Staging Handbook, edn 6. New York: Springer; 2002.
3. Compton CC: Pathology report in colon cancer: What is prognostically important? Dig Dis 1999, 17:67-79.
4. Compton CC: Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000, 124:1016-1025.
5. Nauta R, Stablein DM, Holyoke ED: Survival of patients with stage B2 colon carcinoma. The Gastrointestinal Tumor Study Group experience. Arch Surg 1989, 124:180-182.
6. Gill S, Loprinzi CL, Sargent DJ, et al.: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 2004, 22:1797-1806.
7. Benson AB, 3rd, Schrag D, Somerfield MR, et al.: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22:3408-3419.
8. Moertel CG, Fleming TR, Macdonald JS, et al.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322:352-358.
9. Moertel CG, Fleming TR, Macdonald JS, et al.: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995, 13:2936-2943.
10. Le Voyer TE, Sigurdson ER, Hanlon AL, et al.: Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of inter-group trial INT-0089. J Clin Oncol 2003, 21:2912-2919.
11. Gray RG, Barnwell J, Hills R: QUASAR: a randomized study of adjuvant chemotherapy vs observation including 3238 colorectal cancer patients. Proceedings of the American Society of Clinical Oncology 2004. Alexandria, VA: American Society of Clinical Oncology; 2004.
12. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT 132) Investigators. J Clin Oncol 1999, 17:1356-1363.
13. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
14. Hickish T, Boni C, Navarro M: FOLFOX-4 as adjuvant treatment for stage II colon cancer: subpopulation data from the MOSAIC trial. Proceedings of the American Society of Clinical Oncology 2004. Alexandria, VA American Society of Clinical Oncology; 2004.
15. Schrag D, Rifas-Shiman S, Saltz L, et al.: Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002, 20:3999-4005.
16. Wolmark N, Rockette H, Wickerham DL, et al.: Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990, 8:1466-1475.
17. Wolmark N, Rockette H, Fisher B, et al.: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993, 11:1879-1887.
18. Wolmark N, Rockette H, Mamounas E, et al.: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999, 17:3553-3559.
19. Figueredo A, Charette ML, Maroun J, et al.: Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004, 22:3395-3407.
20. Horn A, Dahl O, Morild I: Venous and neural invasion as predictors of recurrence in rectal adenocarcinoma. Dis Colon Rectum 1991, 34:798-804.
21. Knudsen JB, Nilsson T, Sprechler M, et al.: Venous and nerve invasion as prognostic factors in postoperative survival of patients with resectable cancer of the rectum. Dis Colon Rectum 1983, 26:613-617.
22. Jen J, Kim H, Piantadosi S, et al.: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994, 331:213-221.
23. Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257.
24. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998, 16:3537-3541.
25. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998, 16:301-308.
26. Twelves C, Wong A, Nowacki MP, et al.: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005, 352:2696-2704.
27. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343:905-914.
28. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
29. Saltz LB, Rubin M, Hochster H, et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that express epidermal growth factor receptor (EGFR) [abstract]. Proceedings of the American Society of Clinical Oncology 2001. Alexandria, VA: American Society of Clinical Oncology; 2001. Abstract 7.
30. Saltz LB, Meropol NJ, Loehrer PL Sr, et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208.
31. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
32. Badarinath S, Mitchell EP, Jennis A: Cetuximah plus FOLFOX for colorectal (EXPLORE): preliminary safety analysis of a randomized phase III trial. Proceedings of the American Society of Clinical Oncology 2004. Alexandria, VA: American Society of Clinical Oncology; 2004.
33. Chung KY, Shia J, Kemeny NE, et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005, 23:1803-1810.